CN107002032B - 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型 - Google Patents

三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型 Download PDF

Info

Publication number
CN107002032B
CN107002032B CN201680003627.XA CN201680003627A CN107002032B CN 107002032 B CN107002032 B CN 107002032B CN 201680003627 A CN201680003627 A CN 201680003627A CN 107002032 B CN107002032 B CN 107002032B
Authority
CN
China
Prior art keywords
fibroblast
activity
fibroblasts
expression
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680003627.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107002032A (zh
Inventor
金相宪
崔淙勋
朴贵德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
S Biomedics Co Ltd
Original Assignee
Korea Institute of Science and Technology
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology, Industry Academic Cooperation Foundation of Yonsei University filed Critical Korea Institute of Science and Technology
Priority to CN202110909867.9A priority Critical patent/CN113583946B/zh
Publication of CN107002032A publication Critical patent/CN107002032A/zh
Application granted granted Critical
Publication of CN107002032B publication Critical patent/CN107002032B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN201680003627.XA 2015-11-12 2016-04-19 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型 Active CN107002032B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110909867.9A CN113583946B (zh) 2015-11-12 2016-04-19 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150159011A KR20170055791A (ko) 2015-11-12 2015-11-12 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
KR10-2015-0159011 2015-11-12
PCT/KR2016/004043 WO2017082491A1 (ko) 2015-11-12 2016-04-19 3차원 섬유아세포집합체 및 그를 포함하는 인 비트로 3d 피부 진피 모델

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110909867.9A Division CN113583946B (zh) 2015-11-12 2016-04-19 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型

Publications (2)

Publication Number Publication Date
CN107002032A CN107002032A (zh) 2017-08-01
CN107002032B true CN107002032B (zh) 2021-08-27

Family

ID=58695687

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680003627.XA Active CN107002032B (zh) 2015-11-12 2016-04-19 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型
CN202110909867.9A Active CN113583946B (zh) 2015-11-12 2016-04-19 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110909867.9A Active CN113583946B (zh) 2015-11-12 2016-04-19 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型

Country Status (6)

Country Link
US (1) US10725043B2 (enExample)
EP (1) EP3375865A4 (enExample)
JP (4) JP6933378B2 (enExample)
KR (1) KR20170055791A (enExample)
CN (2) CN107002032B (enExample)
WO (1) WO2017082491A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170055791A (ko) * 2015-11-12 2017-05-22 한국과학기술연구원 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
KR102213922B1 (ko) * 2017-06-30 2021-02-08 (주)아모레퍼시픽 인공피부 제조방법 및 인공피부
US20200392460A1 (en) * 2017-11-10 2020-12-17 Toppan Printing Co., Ltd. Artificial fat tissue and method for producing same, method for producing artificial skin and agent for fat cell culture
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
CN115698315A (zh) * 2020-07-27 2023-02-03 株式会社高丝 全浆分泌调节剂的评价和/或选择方法
KR102365125B1 (ko) * 2020-08-12 2022-02-18 주식회사 티앤알바이오팹 인공 피부 모델을 사용한 피부 탄성 측정 방법 및 피부 첨가제의 스크리닝 혹은 선별 방법
CN114107429A (zh) * 2021-12-02 2022-03-01 云南贝泰妮生物科技集团股份有限公司 一种化妆品原料体外3d皮肤模型屏障修复功效的筛选方法
CN114292894B (zh) * 2022-01-14 2023-08-11 广东悠质检测技术有限公司 一种用体外细胞评价化妆品及原料紧致功效的方法
CN119286771B (zh) * 2024-10-28 2026-07-24 深圳锦时生物科技有限公司 一种高效分离自体皮肤来源的成纤维细胞培养方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03266980A (ja) 1989-03-16 1991-11-27 W R Grace & Co 細胞培養用基材およびそれを用いた細胞集合体の製造方法
JPH0489000A (ja) 1990-05-02 1992-03-23 W R Grace & Co 細胞培養キットおよび細胞傷害試験法
ATE308610T1 (de) * 2000-05-31 2005-11-15 Fraunhofer Ges Forschung Dreidimensionales hautmodell
JP3709369B2 (ja) * 2001-11-13 2005-10-26 丸善製薬株式会社 皮膚化粧料及び美容用飲食品
DE102004039537A1 (de) * 2004-08-13 2006-02-23 Phenion Gmbh & Co. Kg Vernetzte Kollagenmatrix zur Herstellung eines Hautäquivalentes
JP4792566B2 (ja) * 2005-06-01 2011-10-12 財団法人ヒューマンサイエンス振興財団 樹状細胞を含む三次元培養ヒト皮膚モデル
JP2010172240A (ja) * 2009-01-28 2010-08-12 Shiseido Co Ltd エラスチン発現低下を回復する薬剤のスクリーニング方法
JP2010193822A (ja) 2009-02-26 2010-09-09 Toyobo Co Ltd ３次元培養細胞により作成した皮膚同等物およびそれを用いる紫外線の影響の評価方法
KR101094445B1 (ko) * 2009-05-13 2011-12-15 한국과학기술연구원 줄기세포에 대한 접착활성을 갖는 섬유아세포 성장인자의 재조합 단백질 및 이를 이용한 줄기세포의 배양방법
JP2012050406A (ja) 2010-09-03 2012-03-15 Genesis Healthcare Kk 皮膚関連遺伝子の検出方法、並びに該遺伝子を用いた肌情報の提供方法、化粧品の販売システム、化粧品の販売方法及び化粧品成分のスクリーニング方法
CN104263698B (zh) * 2014-09-19 2016-05-18 江苏华亿细胞组织工程有限公司 临床治疗级细胞治疗用成纤维细胞规模化制备人类细胞外基质筛选培养方法
KR20170055791A (ko) 2015-11-12 2017-05-22 한국과학기술연구원 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A novel three-dimensional adipose-derived stem cell cluster for vascular regeneration in ischemic tissue;Park IS等;《CYTOTHERAPY》;20140430;第16卷(第4期);第508-522页 *
Fibroblast cluster formation on 3D collagen matrices requires cell contraction dependent fibronectin matrix organization;da Rocha-Azevedo B等;《Exp Cell Res》;20130215;第319卷(第4期);第483-512页 *
Fibroblast heterogeneity and its implications for engineering organotypic skin models in vitro;Sriram G等;《EUROPEAN JOURNAL OF CELL BIOLOGY》;20150811;第94卷(第11期);第546-555页 *
Low oxygen tension stimulates collagen synthesis and COL1A1 transcription through the action of TGF-β1;Falanga V等;《JOURNAL OF CELLULAR PHYSIOLOGY》;20020219;第191卷(第1期);第42-50页 *
The immobilization of basic fibroblast growth factor on plasma-treated poly(lactide-co-glycolide);Shen H等;《Biometerials》;20080307;第29卷(第15期);第2388-2399页 *

Also Published As

Publication number Publication date
JP7727339B2 (ja) 2025-08-21
CN113583946B (zh) 2024-11-08
KR20170055791A (ko) 2017-05-22
JP2024133695A (ja) 2024-10-02
EP3375865A4 (en) 2019-07-10
JP6933378B2 (ja) 2021-09-08
JP2021180681A (ja) 2021-11-25
WO2017082491A1 (ko) 2017-05-18
JP7235350B2 (ja) 2023-03-08
CN107002032A (zh) 2017-08-01
EP3375865A1 (en) 2018-09-19
JP7525939B2 (ja) 2024-07-31
CN113583946A (zh) 2021-11-02
JP2023058684A (ja) 2023-04-25
US10725043B2 (en) 2020-07-28
US20180252715A1 (en) 2018-09-06
JP2018535646A (ja) 2018-12-06

Similar Documents

Publication Publication Date Title
JP7235350B2 (ja) マルトース結合タンパク質リンカを用いた三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル
Zhu et al. Decellularized extracellular matrix for remodeling bioengineering organoid's microenvironment
US9644183B2 (en) Method for differentiation of stem cells into vascular cells and the induction of angiogenesis using the same
Prestwich Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery
Lutolf et al. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering
Chia et al. Effect of substrate stiffness on pulmonary fibroblast activation by TGF-β
LaNasa et al. Influence of ECM proteins and their analogs on cells cultured on 2-D hydrogels for cardiac muscle tissue engineering
Zhu et al. Cell–cell interactions enhance cartilage zonal development in 3D gradient hydrogels
Evangelatov et al. The evolution of three-dimensional cell cultures towards unimpeded regenerative medicine and tissue engineering
KR101919930B1 (ko) 인 비트로 3차원 세포 배양 모델, 이의 제조 방법 및 이를 이용한 스크리닝 방법
WO2010110596A2 (en) Method for differentiation of stem cells into vascular cells and the induction of angiogenesis using the same
HK40056234A (en) Three-dimensional fibroblast aggregate and in vitro 3d skin dermis model comprising same
HK40056234B (en) Three-dimensional fibroblast aggregate and in vitro 3d skin dermis model comprising same
KR102261934B1 (ko) Mbp-fgf2를 이용한 3차원 섬유아세포집합체를 제조하는 방법
KR102066670B1 (ko) 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
KR102236977B1 (ko) 3차원 섬유아세포집합체 및 그의 생산방법
EP3916080A1 (en) Porous cellular scaffold comprising serum-derived protein, and production method therefor
KR20170132121A (ko) 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
Sari et al. Targeting Mechanobiology of Stem Cells Via Biomaterials for Regenerative Medicine Approaches
Cromeens et al. Critical intestinal cells originate from the host in enteroid-derived tissue-engineered intestine
Wang Signaling from matrix elasticity and TGF-β1 to cells of the cardiac valve
KR20210047839A (ko) 혈청유래 단백질을 포함하는 다공성 세포지지체
KR20210047840A (ko) 조직공학적 사용 또는 질병 치료적 사용을 위한 다공성 세포지지체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200603

Address after: Seoul, South Korea

Applicant after: S Biomedical

Address before: Seoul, South Kerean

Applicant before: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant